Sirnaomics, which counts Walvax Bio, China Resources Group and Charoen Pokphand Group as existing investors, has raised series E funding to advance its drug development activities.
Sirnaomics, a US-based RNAi therapeutics developer backed by vaccine producer Walvax Biotechnology and conglomerates China Resources Group and Charoen Pokphand Group, has closed a $105m series E round.
Investment manager Rotating Boulder Fund led the round and was joined by unspecified new and existing investors.
Founded in 2007, Sirnaomics is developing drug treatments based on a biological process called RNA interference (RNAi), in which small interfering RNAs degrade messenger RNA molecules to regulate gene expression.
The company’s frug candidates are…
